PBS lists medications to reduce severity of COVID-19 19 July 2022 Medications that reduce the severity of COVID-19 are now available on the Pharmaceutical Benefits Scheme (PBS). Oral anti-viral medications, Paxlovid and Lagevrio, can now be prescribed by doctors or authorised nurse practitioners to people living with any type of diabetes who use medication to manage their condition and have another condition. Other conditions include heart or kidney disease or obesity. People living in residential aged care and all people aged 70 and over are also eligible even if they have no risk factors. The medications can be prescribed for: People 50 years of age or older, with two additional risk factors for developing severe COVID-19People 30 years of age or older identifying as Aboriginal or Torres Strait Islander, with two additional risk factors for developing severe diseasePeople 18 years of age or older, who are moderately to severely immunocompromised. The medicines must be started as soon as possible after a diagnosis of COVID-19. If you have developed COVID-19 please speak to your health team about accessing these medicines immediately. It is important to note anti-viral medicines are not intended to be used as substitutes for getting vaccinated against COVID-19. Diabetes Australia continues to recommend people get vaccinated and boosted in line with the latest advice from the Australian Technical Advisory Group on Immunisation.
Blog 4 December 2023 Are you up to date with your COVID-19 vaccination? As we head into the festive season it's a good time to make sure you are up-to-date with your COVID-19 vaccination. Continue Reading
Media releases 22 November 2023 Regional and remote Australians urged to get late flu vaccine People living with diabetes in rural and remote areas are being urged to get their flu shot now after low rates of flu vaccinations have put communities at risk across Australia this year. Continue Reading
News 17 August 2023 Update on Fiasp insulin Diabetes Australia have been consistently talking with both the Federal Government and Novo Nordisk about the need for a solution before 1 October 2023. Continue Reading